Follow
Manish Kohli
Manish Kohli
University of Utah-Huntsman Cancer Institute
Verified email at hci.utah.edu
Title
Cited by
Cited by
Year
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak, CM Tangen, MHA Hussain, PN Lara Jr, JA Jones, ME Taplin, ...
New England Journal of Medicine 351 (15), 1513-1520, 2004
46022004
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer
CJ Sweeney, YH Chen, M Carducci, G Liu, DF Jarrard, M Eisenberger, ...
New England Journal of Medicine 373 (8), 737-746, 2015
28212015
Characterization of human plasma-derived exosomal RNAs by deep sequencing
X Huang, T Yuan, M Tschannen, Z Sun, H Jacob, M Du, M Liang, ...
BMC genomics 14, 1-14, 2013
11382013
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial
CE Kyriakopoulos, YH Chen, MA Carducci, G Liu, DF Jarrard, NM Hahn, ...
Journal of Clinical Oncology 36 (11), 1080, 2018
9192018
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
NB Haas, J Manola, RG Uzzo, KT Flaherty, CG Wood, C Kane, M Jewett, ...
The Lancet 387 (10032), 2008-2016, 2016
6462016
Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer
X Huang, T Yuan, M Liang, M Du, S Xia, R Dittmar, D Wang, W See, ...
European urology 67 (1), 33-41, 2015
6462015
Evaluation and management of patients with heart disease and cancer: cardio-oncology
J Herrmann, A Lerman, NP Sandhu, HR Villarraga, SL Mulvagh, M Kohli
Mayo Clinic Proceedings 89 (9), 1287-1306, 2014
4992014
Nanoparticles for combination drug therapy
L Ma, M Kohli, A Smith
ACS nano 7 (11), 9518-9525, 2013
3532013
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
DP Petrylak, DP Ankerst, CS Jiang, CM Tangen, MHA Hussain, ...
Journal of the National Cancer Institute 98 (8), 516-521, 2006
3272006
Plasma extracellular RNA profiles in healthy and cancer patients
T Yuan, X Huang, M Woodcock, M Du, R Dittmar, Y Wang, S Tsai, M Kohli, ...
Scientific reports 6 (1), 19413, 2016
2792016
Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III …
C Sweeney, YH Chen, MA Carducci, G Liu, DF Jarrard, MA Eisenberger, ...
Journal of Clinical Oncology 32 (15_suppl), LBA2-LBA2, 2014
2692014
Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies
G Gravis, JM Boher, YH Chen, G Liu, K Fizazi, MA Carducci, S Oudard, ...
European urology 73 (6), 847-855, 2018
2272018
Measure transcript integrity using RNA-seq data
L Wang, J Nie, H Sicotte, Y Li, JE Eckel-Passow, S Dasari, PT Vedell, ...
BMC bioinformatics 17, 1-16, 2016
2132016
Phosphorylated RB promotes cancer immunity by inhibiting NF-κB activation and PD-L1 expression
X Jin, D Ding, Y Yan, H Li, B Wang, L Ma, Z Ye, T Ma, Q Wu, ...
Molecular cell 73 (1), 22-35. e6, 2019
1962019
Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance
M Kohli, Y Ho, DW Hillman, JL Van Etten, C Henzler, R Yang, JM Sperger, ...
Clinical Cancer Research 23 (16), 4704-4715, 2017
1352017
miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1
Y Wang, R Lieberman, J Pan, Q Zhang, M Du, P Zhang, M Nevalainen, ...
Molecular cancer 15, 1-11, 2016
1322016
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
JWD Hearn, G AbuAli, CA Reichard, CA Reddy, C Magi-Galluzzi, ...
The Lancet Oncology 17 (10), 1435-1444, 2016
1292016
Activation of P-TEFb by androgen receptor-regulated enhancer RNAs in castration-resistant prostate cancer
Y Zhao, L Wang, S Ren, L Wang, PR Blackburn, MS McNulty, X Gao, ...
Cell reports 15 (3), 599-610, 2016
1162016
Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease
V Kaushal, P Mukunyadzi, RA Dennis, ER Siegel, DE Johnson, M Kohli
Clinical cancer research 11 (2), 584-593, 2005
1122005
Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
PD Grivas, S Daignault, ST Tagawa, DM Nanus, WM Stadler, R Dreicer, ...
Cancer 120 (5), 692-701, 2014
1112014
The system can't perform the operation now. Try again later.
Articles 1–20